Kestra Medical Technologies (NASDAQ:KMTS) Now Covered by Analysts at Piper Sandler

Piper Sandler began coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a research report sent to investors on Monday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $27.00 target price on the stock.

Several other research firms have also weighed in on KMTS. Stifel Nicolaus began coverage on shares of Kestra Medical Technologies in a research report on Monday. They set a “buy” rating and a $28.00 price objective for the company. The Goldman Sachs Group started coverage on Kestra Medical Technologies in a research note on Monday. They issued a “neutral” rating and a $24.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $27.67.

Kestra Medical Technologies Stock Up 4.6 %

Shares of KMTS stock opened at $25.70 on Monday. Kestra Medical Technologies has a 1 year low of $20.00 and a 1 year high of $26.06.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.